Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5308 in Advanced Solid Tumors
NCT07462442Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of QLS5308 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose, Maximum Administered Dose, and Recommended Phase 2 Dose at 12 months and Adverse Events at 48 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QLS5308
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07462442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462442.